Zentalis Pharmaceuticals ZNTL 深 滬
已收盤 02-06 16:00:00 美东时间
2.39
+0.180
+8.14%
華盛通- 最 高2.39
- 今 開2.24
- 成交量 84.19万股
- 最 低 2.17
- 昨 收 2.21
- 總市值 1.55亿
- 52周最高 3.95
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.01
- 委 比 -19.82%
- 總股本 6475.08万
- 歷史最高 87.19
- 量 比 1.08
- 振 幅 9.95%
- 歷史最低 1.01
- 每 手 1
- 風險率 0.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vincent Vultaggio, PAO and PFO, Reports Sale of Zentalis Pharmaceuticals Common Shares
Vincent Vultaggio, PAO and PFO, Reports Sale of Zentalis Pharmaceuticals Common Shares Vincent Vultaggio, PAO and PFO of Zentalis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created
02-05 09:28
Zentalis Pharmaceuticals to Participate in Guggenheim Emerging Outlook Biotech Summit
Zentalis Pharmaceuticals to Participate in Guggenheim Emerging Outlook Biotech Summit Zentalis Pharmaceuticals Inc. will participate in a fireside discussion during Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11th in New York, NY at 3:30 p.m. ET. Disclaimer: This news brief was cr
02-04 05:05
Zentalis outlines 2026 milestones for azenosertib program
Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an update. On January 6, 2026...
01-10 06:49
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 14.1% to...
01-09 05:06
美股牛股 | AI引爆涨价潮！SanDisk飙升超27%；Ventyx 涨超28%
AI引爆涨价潮！Sandisk飙升超27%；有望获礼来超10亿美元收购，Ventyx 涨超28%>>
01-07 15:44
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
Zentalis Pharmaceuticals provided a corporate update highlighting key milestones for 2026, including expected topline data from the DENALI Part 2 trial and initiation of the ASPENOVA Phase 3 trial for azenosertib, a WEE1 inhibitor targeting Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company aims to support accelerated approval and plans to evaluate azenosertib in additional ovarian cancer settings, backed by a strong financi...
01-06 13:00
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
2025-11-13 09:58
Morgan Stanley Maintains Equal-Weight on Zentalis Pharma, Lowers Price Target to $4
Morgan Stanley analyst Matthew Harrison maintains Zentalis Pharma (NASDAQ:ZNTL) with a Equal-Weight and lowers the price target from $8 to $4.
2025-11-13 01:25
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
Zentalis Pharmaceuticals announced the continuation of its Phase 2 DENALI trial of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), targeting topline data by end of 2026, with potential for accelerated FDA approval. The company reported $280.7 million in cash, supporting operations into late 2027, along with decreased R&D and G&A expenses. Additionally, the TETON trial in uterine serous carcinoma completed enrollment.
2025-11-10 21:05
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals granted non-qualified stock options to purchase 17,000 shares to a newly hired employee under the 2022 Inducement Plan. The options have an exercise price of $1.44 and vest over four years. Zentalis is developing a potentially first-in-class WEE1 inhibitor for ovarian cancer patients.
2025-11-03 22:25
